<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03381404</url>
  </required_header>
  <id_info>
    <org_study_id>MT-8554-E07</org_study_id>
    <secondary_id>2017-002830-21</secondary_id>
    <nct_id>NCT03381404</nct_id>
  </id_info>
  <brief_title>Mass Balance Study With MT-8554</brief_title>
  <acronym>MT-8554 MB</acronym>
  <official_title>An Open-label, Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C]-MT-8554 After a Single Oral Dose to Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Development America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Development America, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-centre, open-label, mass balance study in healthy male subjects utilising a
      single oral dose of [14C] MT 8554.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 19, 2017</start_date>
  <completion_date type="Actual">January 29, 2018</completion_date>
  <primary_completion_date type="Actual">January 29, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open Label</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total radioactivity in urine and faeces</measure>
    <time_frame>Up to 14 Days after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration [Cmax]</measure>
    <time_frame>Up to 14 Days after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time at which Cmax occurs [tmax]</measure>
    <time_frame>Up to 14 Days after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to the last measurable concentration [AUC0-last]</measure>
    <time_frame>Up to 14 Days after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal elimination half-life [t1/2]</measure>
    <time_frame>Up to 14 Days after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal elimination rate constant [Kel]</measure>
    <time_frame>Up to 14 Days after dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability as measured by adverse events (AEs)</measure>
    <time_frame>Up to 14 Days after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability as measured by vital signs</measure>
    <time_frame>Up to 14 Days after dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>[14C] MT-8554</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C] MT-8554</intervention_name>
    <description>14-C MT-8554</description>
    <arm_group_label>[14C] MT-8554</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Able to provide written informed consent to participate in this study after reading
             the participant information sheet and informed consent form and after having the
             opportunity to discuss the study with the Investigator or designee.

          -  2. Healthy and free from clinically significant illness or disease as determined by
             medical history, physical examination, laboratory and other tests at Screening and Day
             1.

          -  3. Male Caucasian subjects, aged 30 to 55 years (inclusive) at Screening.

          -  4. A body weight of ≥60 kg and a body mass index (Quetelet index) ranging from 18 to
             30 kg/m2 (inclusive) at Screening or Day 1.

          -  5. Subjects and partners agree to use contraception throughout the study as detailed
             in the Protocol body.

          -  6. In the Investigator's opinion, subject is able to understand the nature of the
             study and any risks involved in participation, and willing to cooperate and comply
             with the Protocol restrictions and requirements.

          -  7. Regular daily bowel movements (i.e., production of at least one stool per day).

        Exclusion Criteria:

          -  1. Previously having received MT-8554.

          -  2. Participation in more than three clinical studies involving administration of an
             IMP in the previous year, or any study within 12 weeks (or, if relevant, five
             half-lives, whichever is the longer) prior to dosing.

          -  3. Presence or history of severe adverse reaction or allergy to any medicinal product
             that is of clinical significance.

          -  4. Subjects who have received any prescribed systemic or topical medication within 14
             days (or, if relevant, five half-lives, whichever is longer) prior to dosing unless,
             in the opinion of the Investigator and Sponsor, the medication will not interfere with
             the study procedures or compromise safety. Subjects who have received slow release
             medicinal formulations considered to still be active within 14 days (or, if relevant,
             five half-lives, whichever is longer) prior to dosing will also be excluded unless, in
             the opinion of the Investigator or Sponsor, the medication will not interfere with the
             study procedures or compromise subject safety.

          -  5. Subjects who have used any non-prescribed systemic or topical medication (including
             herbal remedies) within 7 days (or, if relevant, five half-lives, whichever is longer)
             prior to dosing unless, in the opinion of the Investigator and Sponsor, the medication
             will not interfere with the study procedures or compromise subject safety. Occasional
             use (2 g/day for 3 days) of paracetamol (acetaminophen) for mild analgesia is
             permitted.

          -  6. Subjects who have received any medications, including St John's Wort, known to
             chronically alter drug absorption or elimination processes within 30 days (or, if
             relevant, five half-lives, whichever is longer) prior to dosing unless, in the opinion
             of the Investigator and Sponsor, the medication will not interfere with the study
             procedures or compromise subject safety.

          -  7. Clinically significant (in the opinion of the Investigator) endocrine, thyroid,
             hepatic (including Gilbert's syndrome), respiratory, gastrointestinal, renal,
             cardiovascular disease or history (within the last 2 years) of any significant
             psychiatric/psychotic illness disorder (including anxiety, depression and reactive
             depression).

          -  8. Clinically relevant abnormal medical history, physical findings or laboratory
             values at Screening or Day 1 that could interfere with the objectives of the study or
             compromise subject safety, as judged by the Investigator.

          -  9. Subjects with aspartate aminotransferase, alanine aminotransferase ≥1.5 × upper
             limit of normal or total bilirubin or creatine kinase above the reference range at
             Screening or Day 1.

          -  10. Subjects with creatinine clearance &lt;60 mL/min (calculated using the
             Cockcroft-Gault-formula) at Screening.

          -  11. Family history of long or short QT syndrome, syncope of unknown cause or Torsades
             de Pointes.

          -  12. Clinically significant 12-lead electrocardiogram (ECG) abnormalities, including
             subjects with corrected QT interval using Fridericia's formula (QTcF) of &gt;450 ms, at
             Screening or Day 1, confirmed by repeat assessment.

          -  13. Blood pressure (supine) at Screening or Day 1 outside the range of 90 to 140 mmHg
             (systolic) or 50 to 90 mmHg (diastolic) and pulse rate outside the range of 40 to 100
             beats per minute, confirmed by repeat assessment. Evidence of postural hypotension at
             Screening defined as a decrease of &gt;20 mmHg in systolic or &gt;10 mmHg in diastolic blood
             pressure between the supine and standing position, confirmed by repeat assessment.

          -  14. Tympanic body temperature at Day 1 that is outside the local reference range
             (35.5°C to 37.8°C), confirmed by repeat assessment.

          -  15. Excessive consumption of food or drink containing caffeine, including coffee, tea,
             cola, energy drinks or chocolates (≥5 cups of coffee or equivalent per day).

          -  16. Presence or history of drug abuse (as defined by Diagnostic and Statistical Manual
             of Mental Disorders [DSM-V] criteria) or a positive urine test for drugs of abuse at
             Screening or Day 1.

          -  17. Presence or history (in the last 2 years) of alcohol abuse, or intake of more than
             28 units/224 g of alcohol weekly or a positive breath test for alcohol at Screening or
             Day 1. One unit/8 g is equivalent to a half-pint (280 mL) of beer or one measure (25
             mL) of spirits or one glass (125 mL) of wine.

          -  18. Subjects who use tobacco or nicotine-containing products (cigarettes, snuff,
             chewing tobacco, cigars, pipes, e cigarettes or nicotine-replacement products) within
             3 months prior to dosing, or positive urine cotinine test at Screening or Day 1.

          -  19. Test positive for hepatitis B surface antigen, hepatitis B core antibody,
             hepatitis C antibody or human immunodeficiency virus (HIV) 1 and HIV 2 antibodies at
             Screening.

          -  20. Donate one or more units of blood (450 mL) within 3 months prior to Screening, or
             plasma within 7 days prior to Screening, or platelets within 6 weeks prior to
             Screening, or intention to donate blood within 3 months after the last scheduled
             visit.

          -  21. Consumption of food or drink containing red wine, Seville oranges (including
             marmalade), liquorice, cranberry (including fruit juice) or grapefruit (including
             fruit juice) from 7 days prior to Day 1.

          -  22. Any surgical or medical condition which might significantly alter the absorption,
             distribution, metabolism or excretion of drugs, or which may jeopardise the subject in
             case of participation in the study. The Investigator should be guided by evidence of
             any of the following:

          -  23. History of irritable bowel syndrome, or other manifestation of abnormal bowel
             habit (e.g., diarrhoea, constipation);

          -  24. History of inflammatory bowel disease, gastritis, ulcers, gastrointestinal or
             rectal bleeding;

          -  25. History of major gastrointestinal tract surgery such as gastrectomy,
             gastroenterostomy or bowel resection;

          -  26. History or clinical evidence of pancreatic injury or pancreatitis.

          -  27. Radiation exposure, excluding background radiation but including that from the
             present study, diagnostic X-rays and other medical exposures, exceeding 5 mSv in the
             last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as
             defined in the Ionising Radiation Regulations 1999, shall participate in the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Head of Clinical Development,</last_name>
    <role>Study Director</role>
    <affiliation>Mitsubishi Tanabe Pharma Development America, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational center</name>
      <address>
        <city>City Name</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2017</study_first_submitted>
  <study_first_submitted_qc>December 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 22, 2017</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mass Balance Study with MT-8554</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

